- Home
- ADCT vs CRMD Comparison
ADCT vs CRMD Comparison
Compare ADCT & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- CRMD
- Stock Information
- Founded
- ADCT 2011
- CRMD 2006
- Country
- ADCT Switzerland
- CRMD United States
- Employees
- ADCT N/A
- CRMD N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- ADCT Health Care
- CRMD Health Care
- Exchange
- ADCT Nasdaq
- CRMD Nasdaq
- Market Cap
- ADCT 260.9M
- CRMD 279.7M
- IPO Year
- ADCT 2020
- CRMD 2010
- Fundamental
- Price
- ADCT $3.14
- CRMD $10.49
- Analyst Decision
- ADCT Strong Buy
- CRMD Strong Buy
- Analyst Count
- ADCT 5
- CRMD 5
- Target Price
- ADCT $8.00
- CRMD $12.60
- AVG Volume (30 Days)
- ADCT 400.0K
- CRMD 942.0K
- Earning Date
- ADCT 11-05-2024
- CRMD 11-12-2024
- Dividend Yield
- ADCT N/A
- CRMD N/A
- EPS Growth
- ADCT N/A
- CRMD N/A
- EPS
- ADCT N/A
- CRMD N/A
- Revenue
- ADCT $66,745,999.00
- CRMD $806,119.00
- Revenue This Year
- ADCT $6.58
- CRMD N/A
- Revenue Next Year
- ADCT $14.28
- CRMD $206.77
- P/E Ratio
- ADCT N/A
- CRMD N/A
- Revenue Growth
- ADCT N/A
- CRMD 2107.40
- 52 Week Low
- ADCT $0.36
- CRMD $2.57
- 52 Week High
- ADCT $6.04
- CRMD $10.66
- Technical
- Relative Strength Index (RSI)
- ADCT 52.52
- CRMD 84.30
- Support Level
- ADCT $2.93
- CRMD $9.67
- Resistance Level
- ADCT $3.11
- CRMD $10.66
- Average True Range (ATR)
- ADCT 0.21
- CRMD 0.46
- MACD
- ADCT 0.00
- CRMD 0.08
- Stochastic Oscillator
- ADCT 58.67
- CRMD 93.88
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.